We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04242147
Recruitment Status : Recruiting
First Posted : January 27, 2020
Last Update Posted : January 26, 2023
Sponsor:
Information provided by (Responsible Party):
Sanofi ( Kadmon, a Sanofi Company )

Brief Summary:
This is a Phase1, open-label, sequential dose-escalation and dose-expansion study of KD033 (SAR445710) in adult subjects with advanced or metastatic solid tumors. The main purpose of this study is to test KD033 (SAR445710) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks and when given weekly. Additional purposes of the study are to find out whether the study drug has anti-cancer effects and how the study drug is processed by the body.

Condition or disease Intervention/treatment Phase
Solid Tumor Drug: KD033 (SAR445710) Phase 1

Detailed Description:
The foreseen treatment duration is until disease progression, unacceptable toxicity, criterion for withdrawal or for a maximum of 2 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metastatic or Locally Advanced Solid Tumors
Actual Study Start Date : June 3, 2020
Estimated Primary Completion Date : July 25, 2025
Estimated Study Completion Date : September 30, 2025

Arm Intervention/treatment
Experimental: Bi-weekly Monotherapy Dose Escalation (Q2W)
KD033 (SAR445710) will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration every 2 weeks (Q2W).
Drug: KD033 (SAR445710)
Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)

Experimental: Weekly Monotherapy Dose Escalation (Q1W)
KD033 (SAR445710) will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration once a week (QW) for 6 weeks and then every 2 week-dosing.
Drug: KD033 (SAR445710)
Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)

Experimental: Dose Expansion
KD033 (SAR445710) will be administered at recommended dose/schedule for expansion
Drug: KD033 (SAR445710)
Pharmaceutical form: Solution for infusion Route of administration: intravenous (IV)




Primary Outcome Measures :
  1. Occurrence of Dose Limiting Toxicities (DLTs) [ Time Frame: Up to 28 days ]
    To evaluate the number of subjects who experienced DLTs during the dose escalation phase

  2. Treatment Emergent Adverse Events (TEAEs) and Treatment-related AEs by Severity [ Time Frame: Up to 30 days after last treatment ]
    To evaluate the number of TEAEs and treatment-related AEs by severity for all dose groups/cohorts according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)


Secondary Outcome Measures :
  1. Best Overall Response (BOR) [ Time Frame: Through study completion, an expected average of 1 year ]
    To evaluate the best overall response from study treatment according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) and Immune Response Evaluation Criteria in Solid Tumors (iRECIST) criteria per Investigator assessment

  2. Duration Of Response (DOR) [ Time Frame: Through study completion, an expected average of 1 year ]
    To evaluate the duration of response from study treatment according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) and Immune Response Evaluation Criteria in Solid Tumors (iRECIST) criteria per Investigator assessment

  3. Exploration of KD033 (SAR445710) Pharmacokinetic (PK) Profile - AUC [ Time Frame: Through study completion, an expected average of 1 year ]
    Area under the concentration versus time curve (AUC)

  4. Exploration of KD033 (SAR445710) Pharmacokinetic (PK) Profile - Cmax [ Time Frame: Through study completion, an expected average of 1 year ]
    Maximum plasma concentration observed (Cmax)

  5. Exploration of Anti-KD033 (SAR445710) Antibodies [ Time Frame: Through study completion, an expected average of 1 year ]
    To evaluate serum titers and assessment of neutralization of anti-KD033 (SAR445710) antibodies using blood samples collected during the dose escalation and dose expansion phases



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed/documented advanced and/or metastatic solid tumor with at least one tumor lesion of location accessible to biopsy per clinical judgement of treating physician.
  • Subjects must be willing to provide a tumor biopsy at the following time points: Pre-treatment and at Cycle 4, Day 1. All other study eligibility criteria must be met before any biopsy sample is obtained.
  • Measurable disease at baseline per RECIST v1.1 guidelines.
  • Life expectancy of at least 3 months.
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) score ≤ 1.
  • Adequate organ and bone marrow functions.
  • All toxicities related to prior radiotherapy, chemotherapy, or surgical procedure must have recovered to baseline or Grade ≤ 1 based on NCI-CTCAE v5.0 except alopecia (any grade), Grade 2 peripheral neuropathy and adverse events that are clinically non-significant or stable on supportive care.
  • All subjects, male and female, who are not surgically sterilized or postmenopausal must agree to use 'highly effective methods of contraception' during the study and for at least 60 days after the last dose of KD033 (SAR445710).
  • Women of childbearing potential must have a negative pregnancy test within 7 days prior to KD033 (SAR445710) treatment.
  • Ability to understand the purpose of the study, provide signed and dated informed consent from the subject/legal representative prior to performing any protocol-related procedures and able to comply with the study procedures and any locally required authorization.

Exclusion Criteria:

  • Use of immunotherapy, biological therapy, cytokine therapy < 21 days prior to the first dose of study drug.
  • Use of immunomodulating agents < 21 days prior to the first dose of study drug.
  • Use of chemotherapy and approved tyrosine kinase inhibitor (TKI) therapy < 14 days prior to the first dose of study drug.
  • Anti PD-L1 or anti PD-1 therapy < 6 weeks prior to the first dose of study drug.
  • Radiotherapy within 14 days before the start of trial treatment (prior diagnostic biopsy is permitted), with the exception of palliative radiation as described: patients assigned to radiotherapy require at least 1 additional lesion that can be safely irradiated while sparing the index lesion(s), and for which radiation at the limited, palliative doses contemplated would be considered medically appropriate; The lesion should be causing some signs or symptoms (e.g., tumor-related pain), for which radiation is indicated per the physician's standard clinical practice.
  • Use of any investigational drug or have major surgery within 28 days before the start of trial treatment
  • Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required systemic immunosuppressive treatments.
  • Systemic therapy with immunosuppressive agents including corticosteroids within 14 days before the start of trial treatment with the exception of corticosteroid replacement therapy for adrenal insufficiency
  • Rapidly progressive disease which, in the opinion of Investigator, may predispose to inability to tolerate treatment or trial procedure.
  • History or clinical evidence of central nervous system primary tumors or metastases including leptomeningeal metastases unless they have been previously treated, demonstrated no progression at least 1 months, are asymptomatic and have had no requirement for steroids or enzyme inducing anticonvulsants in the last 14 days before Screening - Subjects with suspected brain metastases at Screening should undergo a CT/MRI of the brain prior to study entry.
  • Receipt of any organ transplantation including hematopoietic cell transplantation.
  • Has a paraneoplastic syndrome of autoimmune nature.
  • History of interstitial lung disease or severe obstructive pulmonary disease.
  • Clinically significant cardiovascular/cerebrovascular disease.
  • QTc(F) interval > 450 ms for men or > 470 ms for women)
  • Left ventricular ejection fraction (LVEF) < 50% as measured by an echocardiogram (ECHO).
  • Active infection requiring therapy.
  • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding.
  • Pregnant or breast-feeding women
  • Known severe hypersensitivity reactions to monoclonal antibodies, any history of or recent (within 6 months) of anaphylaxis
  • Vaccine administration within 4 weeks of investigational drug administration.
  • Vaccination with live vaccines while on trial is prohibited. Administration of inactivated vaccines like inactivated influenza vaccines is allowed. COVID-19 vaccines are approved to be administered prior to KD033 (SAR445710) administration and during the treatment phase, however, it is preferred to not vaccinate during the 28-day DLT period.

Note: Other protocol-defined exclusion criteria could apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04242147


Contacts
Layout table for location contacts
Contact: Trial Transparency email recommended (Toll free number for US & Canada) 800-633-1610 ext option 6 Contact-US@sanofi.com

Locations
Layout table for location information
United States, California
UCLA Hematology/Oncology, 2020 Santa Monica Boulevard, Suite 600 - Site 042 Recruiting
Santa Monica, California, United States, 90404
Contact: Christopher Lim    310-633-8400 ext 16043    christopherlim@mednet.ucla.edu   
Contact: MD         
Principal Investigator: Lee S Rosen, MD         
United States, New York
Roswell Park Cancer Institute - 665 Elm St - Site 062 Recruiting
Buffalo, New York, United States, 14263
Contact: John Pineda    716-845-1300 ext 5054    John.Pineda@RoswellPark.org   
Principal Investigator: Christos Fountzilas, MD         
United States, Pennsylvania
Fox Chase Cancer Center - 333 Cottman Avenue - Site 141 Recruiting
Philadelphia, Pennsylvania, United States, 19111
Contact: Dana Haagen, BA, BS    215-214-3908    Dana.Haagen@fccc.edu   
Principal Investigator: Anthony Olszanski, MD         
University of Pittsburgh Medical Center - Hillman Cancer Center - 5150 Centre Avenue, Suite 301 - Site 132 Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Contact: Sarah Behr    412-623-6028    IDDCReferrals@upmc.edu   
Principal Investigator: Jason Luke, MD, FACP         
Sponsors and Collaborators
Kadmon, a Sanofi Company
Layout table for additonal information
Responsible Party: Kadmon, a Sanofi Company
ClinicalTrials.gov Identifier: NCT04242147    
Other Study ID Numbers: TED17644
KD033-101 ( Other Identifier: Kadmon )
U1111-1279-2406 ( Registry Identifier: ICTRP )
2022-503080-15 ( Other Identifier: CTIS )
First Posted: January 27, 2020    Key Record Dates
Last Update Posted: January 26, 2023
Last Verified: January 23, 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms